Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia (Q30884291)

27 June 2017

1 reference

title

Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia (English)

1 reference

27 June 2017

0 references

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

3 April 2024

2

Matcheri S Keshavan

1 reference

27 June 2017

Ravinder Reddy

1

1 reference

PubMed ID

14623493

27 June 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

PubMed ID

14623493

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623493

3 April 2024

publication date

1 December 2003

1 reference

full work available at URL

27 June 2017

5

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0952327803001637?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

https://api.elsevier.com/content/article/PII:S0952327803001637?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Prostaglandins, Leukotrienes and Essential Fatty Acids

3 April 2024

published in

1 reference

27 June 2017

69

1 reference

27 June 2017

401-405

1 reference

27 June 2017

6

1 reference

Magnetic resonance spectroscopy in psychiatry: potential, pitfalls, and promise

27 June 2017

1

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part I.

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part II.

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients.

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Biological correlates of slow wave sleep deficits in functional psychoses: 31P-magnetic resonance spectroscopy.

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls.

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Magnetic resonance imaging volumetric and phosphorus 31 magnetic resonance spectroscopy measurements in schizophrenia

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia.

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls.

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms.

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique--preliminary findings.

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics--a study including 50 patients and 36 controls.

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Increase of phosphodiesters during neuroleptic treatment of schizophrenics: a longitudinal 31P-magnetic resonance spectroscopic study.

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo 31P MRS study

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

31P-MR spectroscopy in children and adolescents with a familial risk of schizophrenia.

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

The membrane hypothesis of schizophrenia

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

In vivo 13C nuclear magnetic resonance: applications and current limitations for noninvasive assessment of fatty acid status

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes.

3 April 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: a comparison of rat neural and red cell membrane phospholipids.

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Modification of milk formula to enhance accretion of long-chain n-6 and n-3 polyunsaturated fatty acids in artificially reared infant rats.

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Docosahexaenoic acid is transferred through maternal diet to milk and to tissues of natural milk-fed piglets

3 April 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants.

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 Tesla

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Effects of tumbling and lateral diffusion on phosphatidylcholine model membrane 31P-NMR lineshapes

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets.

3 April 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers

3 April 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.011

3 April 2024

Identifiers

1 reference

27 June 2017

1 reference

PubMed ID

14623493